Special Issue "Challenges in the Treatment of Myelodysplastic Syndrome"
A special issue of Hemato (ISSN 2673-6357). This special issue belongs to the section "Chronic Myeloid Disease".
Deadline for manuscript submissions: closed (31 May 2021) | Viewed by 21904
Special Issue Editors
Interests: myelodyspalstic syndromes; acute and chronic myeloid leukemias
2. Bone Marrow Transplantation Department, French Reference Center for Aplastic Anemia and PNH, Paris, France
Interests: allogeneic stem cell transplantation; graft-versus-host disease; immune defect and other post-transplant complications; myelodysplastic syndrome; myeloproliferative disorders; aplastic anemia
Special Issue Information
Dear Colleagues,
This Special Issue is dedicated to “MDS from Bench to Bedside”, and is conceived under the direction of Pierre Fenaux who has made efforts to continuously contribute to the field over the last 35 years.
During the last decade, the explosion of molecular techniques has enabled better understanding of MDS and AML pathogenetic mechanisms, clonal heterogeneity, and individual diversity. Based on recent findings, new MDS entities have emerged. Alterations in hematopoietic processes, from clonal hematopoiesis of indeterminate potential to lower- and higher-risk MDS have been characterized and analyzed. Molecular signatures of MDS have been used to identify innovative and effective target therapy. While stem cell transplant is still the only curative approach for MDS, combining therapies with different targets and mechanisms of action may be promising to relieve symptoms related to MDS or to decrease the risk of progression to AML.
In this Special Issue, we aim to highlight some of the most important and topical issues, including recent advances, controversies, and challenges in the treatment of MDS.
Prof. Dr. Valeria Santini
Dr. Marie Robin
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hemato is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- MDS
- genomic
- targeted therapy
- transplantation